Form 4: Health Catalyst Executive Benjamin Landry Sells Shares Under 10b5-1 Trading Plan

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 13,827 shares of common stock at a price of $4.5462 per share on March 6, 2025, under a pre-arranged trading plan.

Summary

• On March 6, 2025, Benjamin Landry, the General Counsel of Health Catalyst, Inc., sold 13,827 shares of the company's common stock.
• The sale was executed at a price of $4.5462 per share.
• This transaction was conducted under a pre-existing written trading plan adopted on March 1, 2024, in accordance with Rule 10b5-1.
• Following the sale, Landry directly owns 160,437 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Insider sales, especially those conducted under 10b5-1 plans, are common in publicly traded companies. They can provide liquidity for executives but are often scrutinized by investors for insights into management's perspective on the company's future prospects. The existence of a pre-arranged plan mitigates concerns about trading on inside information.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among corporate executives to sell shares over time while avoiding accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of Health Catalyst, suggesting it's likely for personal financial planning rather than a major shift in sentiment.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment if misinterpreted as a lack of confidence by the General Counsel, although the 10b5-1 plan context mitigates this.

Key Dates